Edition:
India

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

17.81USD
18 Apr 2019
Change (% chg)

$0.10 (+0.56%)
Prev Close
$17.71
Open
$17.69
Day's High
$17.96
Day's Low
$17.04
Volume
132,719
Avg. Vol
129,562
52-wk High
$69.23
52-wk Low
$13.92

Latest Key Developments (Source: Significant Developments)

G1 Therapeutics announces positive topline results from randomized phase 2 trial of trilaciclib showing multi-lineage myelopreservation benefits in 2nd-/3rd-line small cell lung cancer
Thursday, 20 Dec 2018 

Dec 19 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM RANDOMIZED PHASE 2 TRIAL OF TRILACICLIB SHOWING MULTI-LINEAGE MYELOPRESERVATION BENEFITS IN 2ND-/3RD-LINE SMALL CELL LUNG CANCER.G1 THERAPEUTICS INC - ACHIEVED BOTH PRIMARY ENDPOINTS: STATISTICALLY SIGNIFICANT REDUCTIONS IN DURATION AND OCCURRENCE OF GRADE 4 NEUTROPENIA.G1 THERAPEUTICS- CLINICALLY MEANINGFUL REDUCTIONS IN RATES OF GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) USAGE AND RED BLOOD CELL (RBC) TRANSFUSIONS.G1 THERAPEUTICS INC - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED TRIALS.G1 THERAPEUTICS INC - TREATMENT WAS WELL TOLERATED.  Full Article

G1 Therapeutics Announces Positive Myelopreservation Data From Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial Of Trilaciclib In Combination With Chemotherapy/Tecentriq
Tuesday, 27 Nov 2018 

Nov 26 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS ANNOUNCES POSITIVE MYELOPRESERVATION DATA FROM RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL OF TRILACICLIB IN COMBINATION WITH CHEMOTHERAPY/TECENTRIQ® IN FIRST-LINE SMALL CELL LUNG CANCER.G1 THERAPEUTICS INC - STATISTICALLY SIGNIFICANT IMPROVEMENTS IN BOTH PRIMARY ENDPOINTS OF OCCURRENCE OF GRADE 4 NEUTROPENIA.G1 THERAPEUTICS - STATISTICALLY SIGNIFICANT REDUCTION IN GRADE 4 THROMBOCYTOPENIA AND CLINICALLY MEANINGFUL REDUCTION IN RED BLOOD CELL TRANSFUSIONS.G1 THERAPEUTICS INC - PLAN TO REQUEST MEETINGS WITH U.S. AND EUROPEAN REGULATORY AGENCIES IN EARLY 2019 TO DISCUSS TOTALITY OF CLINICAL DATA.  Full Article

G1 Therapeutics Announces Proposed Offering Of Common Stock
Tuesday, 18 Sep 2018 

Sept 17 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.SAYS OFFERING 3.00 MILLION COMMON SHARES.  Full Article

G1 Therapeutics To Report Myelopreservation Data From Randomized Phase 2 Trial Of Trilaciclib
Monday, 17 Sep 2018 

Sept 17 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS TO REPORT MYELOPRESERVATION DATA FROM RANDOMIZED PHASE 2 TRIAL OF TRILACICLIB/CHEMOTHERAPY/TECENTRIQ IN SMALL CELL LUNG CANCER IN FOURTH QUARTER 2018.G1 THERAPEUTICS INC - MYELOPRESERVATION RESULTS FROM TRIAL WILL BE REPORTED IN Q4 OF 2018.G1 THERAPEUTICS INC - MYELOPRESERVATION RESULTS ARE NOW PRIMARY OUTCOME AND OVERALL SURVIVAL IS BEING ASSESSED AS A SECONDARY OUTCOME.G1 THERAPEUTICS-EXPEDITING ANALYSES OF MYELOPRESERVATION DATA FROM RANDOMIZED PHASE 2 TRIAL OF TRILACICLIB IN COMBINATION WITH CHEMOTHERAPY, TECENTRIQ.  Full Article

G1 Therapeutics Announces Initiation Of Phase 1B/2 Clinical Trial Of G1T38 In Combination With Tagrisso
Monday, 16 Apr 2018 

April 16 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1B/2 CLINICAL TRIAL OF G1T38 IN COMBINATION WITH TAGRISSO FOR EGFR-MUTANT NON-SMALL CELL LUNG CANCER.G1 THERAPEUTICS INC - ASTRAZENECA IS PROVIDING TAGRISSO FOR PHASE 1B/2 CLINICAL TRIAL UNDER NON-EXCLUSIVE CLINICAL TRIAL COLLABORATION AGREEMENT.G1 THERAPEUTICS - OPEN-LABEL TRIAL IS EXPECTED TO ENROLL APPROXIMATELY 145 PARTICIPANTS IN TWO PARTS.  Full Article

G1 Therapeutics Files For Offering Of 3 Mln Shares
Tuesday, 6 Mar 2018 

March 5 (Reuters) - G1 Therapeutics Inc ::FILES FOR OFFERING OF 3 MILLION SHARES OF ITS COMMON STOCK.  Full Article

G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer
Monday, 5 Mar 2018 

March 5 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS ANNOUNCES POSITIVE TRILACICLIB PHASE 2A TOPLINE DATA SHOWING ROBUST MYELOPRESERVATION BENEFITS IN PATIENTS WITH SMALL CELL LUNG CANCER.G1 THERAPEUTICS - CURRENTLY CONDUCTING TWO ADDITIONAL CLINICAL TRIALS OF TRILACICLIB WITH PRELIMINARY DATA FROM BOTH EXPECTED IN Q4 2018.G1 THERAPEUTICS - TRILACICLIB REDUCED CLINICALLY RELEVANT CONSEQUENCES OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION VERSUS PLACEBO.G1 THERAPEUTICS INC - STATISTICALLY SIGNIFICANT RESULTS FROM PHASE 2A TRIAL EVALUATING TRILACICLIB.  Full Article

G1 Therapeutics Qtrly Net Loss Per Share $0.60
Thursday, 22 Feb 2018 

Feb 21 (Reuters) - G1 Therapeutics Inc ::G1 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS.QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $0.60.Q1 EARNINGS PER SHARE VIEW $-0.60 -- THOMSON REUTERS I/B/E/S.  Full Article

G1 Therapeutics qtrly ‍loss per share $0.55
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - G1 Therapeutics Inc ::G1 therapeutics reports third quarter 2017 financial results and recent operational highlights.G1 therapeutics inc - qtrly ‍loss per share $0.55.G1 therapeutics inc - qtrly loss per share ‍$0.55​.Q3 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.G1 therapeutics inc- ‍cash, cash equivalents and short-term investments totaled $118.4 million as of sept 30, 2017, versus $47.3 million as of dec 31, 2016​.  Full Article

G1 Therapeutics Inc appoints Barclay (Buck) Phillips as CFO and SVP, corporate development​
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - G1 Therapeutics Inc ::G1 Therapeutics Inc - appoints barclay (buck) phillips as chief financial officer and senior vice president, corporate development​.G1 Therapeutics Inc - ‍G1 announced that chief business officer Greg Mossinghoff will depart company in January of 2018​.  Full Article